JF

Jim Faulkner

Independent Consultant specialising in Cell and Gene Therapy development. Non-Executive Director

London, England

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Cell Therapy
Gene Therapy
Non-Executive Director
Technology Transfer
Biopharmaceuticals
Biotechnology
CMC
Pharmaceutical Industry
Drug Development
Life Sciences
Clinical Research
Regulatory Affairs
Clinical Development
Drug Discovery
Biochemistry
Clinical Trials
GMP
Molecular Biology
R&D
Research and Development (R&D)

Education

Lists including Jim

AP
AO
AS
AN

Based in UK

1884 people

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Work Experience

JDB BioConsulting

2023

  • Independent Consultant

    2023

Ca
Cell and Gene Therapy Catapult

2024

  • Non Executive Board Member

    2024

VT
Vitarka Therapeutics

2024

  • Non Executive Board Member

    2024

AT
Ascidian Therapeutics

2020 - 2024

  • Chief Technical Advisor

    2024 - 2024

  • Chief Technology Officer

    2020 - 2024

AT
Apple Tree Partners

2020 - 2023

  • Venture Partner

    2020 - 2023

AL
Autolus Ltd.

2015 - 2019

  • SVP, Product Delivery

    2015 - 2019

G
GlaxoSmithKline

1998 - 2015

  • VP, CMC and Supply, Rare Disease Unit

    2010 - 2015

  • Vice President, Biopharm Process Research

    2007 - 2010

  • VP, Early Stage Biopharm Development

    2004 - 2007

  • WW Director, Biopharm Analytical Sciences

    2001 - 2004

  • Section Head, Molecular Analysis

    1998 - 2000

British Biotech

1993 - 1998

  • Team Leader, Biopharmaceutical Analysis

    1993 - 1998

Centre for Applied Microbiology and Research (CAMR)

1987 - 1993

  • Senior Clinical Scientist, Molecular Genetics

    1987 - 1993

VU
Vrije Universiteit Amsterdam (VU Amsterdam)

1986 - 1987

  • Research Assistant, Molecular Genetics

    1986 - 1987